Paper Details

  1. Home
  2. Paper Details

Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies.

Author: Baka-OstrowskaMałgorzata, BolongDavid, BosmanBrigitte, DahlerEllen, DaviesLeon N, FrancoIsrael, HoebekePiet, NewgreenDonald, SnijderRobert, StroosmaOtto, Vande WalleJohan, VerheggenFrank

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Solifenacin was effective and well tolerated in pediatric patients with neurogenic detrusor overactivity (NDO), suggesting that it is a viable alternative to oxybutynin, the current standard of care.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: The standard recommended treatment for neurogenic detrusor overactivity (NDO) is clean intermittent catheterization combined with an antimuscarinic agent. However, the adverse systemic side-effects of oxybutynin, the most widely used agent, are of concern. OBJECTIVE: To evaluate the e...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jpurol.2019.12.012

データ提供：米国国立医学図書館（NLM）

Solifenacin for Pediatric Neurogenic Detrusor Overactivity: A Promising Alternative

In the field of [pediatric urology], [neurogenic detrusor overactivity (NDO)] poses significant challenges for both patients and caregivers. This research explores the efficacy and safety of [solifenacin] in treating [NDO] in children aged 6 months to 18 years. The authors conducted two phase 3, open-label studies to evaluate the long-term effects of this medication in this population.

Solifenacin: A Viable Option for Pediatric NDO

The research demonstrated the effectiveness and safety of [solifenacin] in treating [NDO] in pediatric patients. The study found clinically significant improvements in [maximum cystometric capacity (MCC)] and other bladder function parameters. This finding offers a promising alternative to [oxybutynin], the current standard of care, which is often associated with significant side effects.

Improving the Quality of Life for Children with NDO

This research offers hope for children struggling with [NDO], providing a potentially more effective and well-tolerated treatment option. Just as a camel adapts to the challenges of a harsh desert environment, we must continually seek ways to improve the quality of life for children with [NDO], ensuring they can thrive and reach their full potential.

Dr.Camel's Conclusion

This research presents a compelling case for the use of [solifenacin] in treating [NDO] in pediatric patients. The authors' findings offer a promising alternative to existing therapies, highlighting the ongoing search for better and safer treatment options for children with this challenging condition. Just as a camel adapts to the harsh desert environment, we must continue to strive for innovative solutions that improve the lives of children with [NDO] and ensure they can live healthy and fulfilling lives.
Date :
  1. Date Completed 2021-06-21
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

32007426

DOI: Digital Object Identifier

10.1016/j.jpurol.2019.12.012

Related Literature

Article Analysis
・Side Effects of solifenacin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.